An investigation of the differential therapeutic effects of romosozumab on postmenopausal osteoporosis patients with or without rheumatoid arthritis complications: a case–control study

enthalten in: Osteoporosis international | 2024

von Ebina, K. | Nagayama, Y. | Kashii, M. | +11

Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis

enthalten in: Osteoporosis international | 2022

von Kashii, M. | Kamatani, T. | Nagayama, Y. | +3

Baseline serum PINP level is associated with the increase in hip bone mineral density seen with Romosozumab treatment in previously untreated women with osteoporosis

enthalten in: Osteoporosis international | 2022

von Kashii, M. | Kamatani, T. | Nagayama, Y. | +3

Impact of the duration of previous osteoporosis treatment on the effect of romosozumab in patients with postmenopausal osteoporosis

enthalten in: Osteoporosis international | 2022

von Ebina, K. | Etani, Y. | Tsuboi, H. | +14

Impact of the duration of previous osteoporosis treatment on the effect of romosozumab in patients with postmenopausal osteoporosis

enthalten in: Osteoporosis international | 2022

von Ebina, K. | Etani, Y. | Tsuboi, H. | +14